{'fraction_non_alphanumeric': 0.020676691729323307, 'fraction_numerical': 0.011278195488721804, 'mean_word_length': 4.98876404494382, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.

This article summarizes the discussions of a colloquium on oral GPIIb/IIIa receptor blockers in London, U.K. 4 and 5 May 2000, which was convened under the auspices of the European Society of Cardiology. The participants of the meeting are listed in the appendix. Financial support for the meeting was obtained from the European Society of Cardiology and the companies listed in the Appendix. Introduction